CU PARTNERS: NY/LONG ISLAND REGIONAL NODE

这是哥伦比亚大学/纽约州立精神病学研究所（NYSPI）药物滥用研究小组（CU-SA）与长岛犹太(LIJ)-Hillside医院研究部和四家备受尊敬的社区治疗组织（cbo）合作提出的一项建议，其中包括圣卢卡-罗斯福医院、桥广场-麻醉品自由公司、北岸-长岛犹太卫生系统以及治疗社区凤凰之家。这一合作是一种伙伴关系（CU PARTNERS），将与NIDA临床试验网络（CTN）的其他节点合作。CU伙伴在药物滥用治疗研究方面拥有全面的专业知识，这对参与临床试验网络（CTN）至关重要。此外，CU PARTNERS将为CTN提供一些相对独特的优势，包括研究评估、药物滥用者共病精神障碍的治疗、儿童和青少年精神病学、临床试验设计、艾滋病毒风险降低、药物和行为联合治疗、行为科学和国家药物政策方面的专业知识。近几十年来的治疗研究导致了许多药物疗法和行为疗法的发展，用于各种药物依赖问题的各种药物疗法。然而，在很大程度上，这些新疗法并没有得到广泛应用。拟议的节点及其所属的国家网络将启动和实施大型、多地点、随机临床试验，这些试验将由CTPs的工作人员进行。这些试验的目的是评估新疗法的疗效是否能推广到“现实世界”的治疗环境中，传播这些疗法并促进它们的适当使用，以及了解可能干扰新疗法成功适应的问题。更大的目标是让以社区为基础的项目和从业人员作为研究工作的全面合作伙伴参与其中，既为国家的治疗系统注入循证导向，又确保研究本身的设计能够满足临床需求。

This is a proposal from the Columbia University/New York Stat Psychiatric Institute (NYSPI) Substance Abuse Research Group (CU-SA) in collaboration with the Division of Research at the Long Island Jewish (LIJ)-Hillside Hospital and four well-respected community-based treatment organizations (CBOs), the St. Lukes-Roosevelt Hospital, Bridge Plaza-Narco Freedom, Inc., ant the North Shore-Long Island Jewish Health system,as well as the therapeutic community, Phoenix House. This collaboration is a partnership (CU PARTNERS) which will work cooperatively with other nodes in the NIDA Clinical Trial Network (CTN). CU PARTNERS have a full range of expertise in substance abuse treatment research essential for participation in the Clinical Trials Networks (CTN). In addition, CU PARTNERS would offer a number of relatively unique strengths to the CTN, including expertise in research assessment, treatment of comorbid psychiatric disorders in substance abusers, child and adolescent psychiatry, design of clinical trials, HIV risk reduction, combined pharmacologic and behavioral therapy, behavioral science, and national drug policy. Treatment research over recent decades has led to the development of a number os pharmacotherapies and behavioral therapies for various drug therapies for various drug dependence problems. Yet, for the most part, these newer treatments have not seen widespread use. The proposed node, and the national Network of which it would be a part, will initiate and implement large, multisite, randomized clinical trials, which will be carried out by the staff of the CTPs. The aims of these trials will be to evaluate whether the efficacy of the newer therapies generalizes to "real world" treatment settings, to disseminate these treatments and foster their appropriate use, and to understand the problems which may interfere with the successful adaptation of newer treatments. A larger aim is to have community-based programs and practitioners participate as full partners in the research endeavor, both to infuse the Nation's treatment system with an evidence-based orientation, and to ensure that research itself is designed to respond to clinical needs.